A detailed history of Vanguard Group Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 11,994,261 shares of ALNY stock, worth $2.88 Billion. This represents 0.04% of its overall portfolio holdings.

Number of Shares
11,994,261
Previous 11,943,895 0.42%
Holding current value
$2.88 Billion
Previous $2.29 Billion 21.59%
% of portfolio
0.04%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$146.51 - $198.2 $7.38 Million - $9.98 Million
50,366 Added 0.42%
11,994,261 $1.79 Billion
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $43.5 Million - $56.4 Million
287,064 Added 2.46%
11,943,895 $2.29 Billion
Q3 2023

Nov 14, 2023

BUY
$170.77 - $211.65 $5.23 Million - $6.48 Million
30,608 Added 0.26%
11,656,831 $2.06 Billion
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $3.34 Million - $3.83 Million
18,056 Added 0.16%
11,626,223 $2.21 Billion
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $18.5 Million - $23.8 Million
101,051 Added 0.88%
11,608,167 $2.33 Billion
Q4 2022

Feb 10, 2023

BUY
$185.53 - $241.31 $84.2 Million - $110 Million
453,808 Added 4.11%
11,507,116 $2.73 Billion
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $1.51 Million - $2.52 Million
10,870 Added 0.1%
11,053,308 $2.21 Billion
Q2 2022

Aug 12, 2022

BUY
$120.42 - $169.29 $25.7 Million - $36.1 Million
213,294 Added 1.97%
11,042,438 $1.61 Billion
Q1 2022

May 13, 2022

BUY
$127.18 - $173.91 $16.1 Million - $22 Million
126,373 Added 1.18%
10,829,144 $1.77 Billion
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $14.1 Million - $18.5 Million
88,189 Added 0.83%
10,702,771 $1.81 Billion
Q3 2021

Nov 12, 2021

BUY
$169.75 - $207.73 $19.8 Million - $24.3 Million
116,888 Added 1.11%
10,614,582 $2 Billion
Q2 2021

Aug 13, 2021

BUY
$128.63 - $176.89 $1.35 Billion - $1.86 Billion
10,497,694 New
10,497,694 $1.78 Billion

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.5B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.